These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10604708)

  • 1. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.
    Manyak MJ; Hinkle GH; Olsen JO; Chiaccherini RP; Partin AW; Piantadosi S; Burgers JK; Texter JH; Neal CE; Libertino JA; Wright GL; Maguire RT
    Urology; 1999 Dec; 54(6):1058-63. PubMed ID: 10604708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
    Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
    Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capromab Pendetide imaging of prostate cancer.
    Haseman MK; Rosenthal SA; Polascik TJ
    Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
    Raj GV; Partin AW; Polascik TJ
    Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
    Rosenthal SA; Haseman MK; Polascik TJ
    Tech Urol; 2001 Mar; 7(1):27-37. PubMed ID: 11272670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer.
    Hardie AD; Rieter WJ; Bradshaw ML; Gordon LL; Young MA; Keane TE
    World J Urol; 2013 Dec; 31(6):1327-32. PubMed ID: 23595605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide.
    Hinkle GH; Burgers JK; Neal CE; Texter JH; Kahn D; Williams RD; Maguire R; Rogers B; Olsen JO; Badalament RA
    Cancer; 1998 Aug; 83(4):739-47. PubMed ID: 9708939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
    Kahn D; Williams RD; Manyak MJ; Haseman MK; Seldin DW; Libertino JA; Maguire RT
    J Urol; 1998 Jun; 159(6):2041-6; discussion 2046-7. PubMed ID: 9598514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer.
    Petronis JD; Regan F; Lin K
    Clin Nucl Med; 1998 Oct; 23(10):672-7. PubMed ID: 9790041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capromab Pendetide immunoscintigraphy: connecting the dots for prostate cancer imaging.
    Manyak MJ
    Cancer Biother Radiopharm; 2000 Apr; 15(2):127-30. PubMed ID: 10803317
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.
    Schuster DM; Savir-Baruch B; Nieh PT; Master VA; Halkar RK; Rossi PJ; Lewis MM; Nye JA; Yu W; Bowman FD; Goodman MM
    Radiology; 2011 Jun; 259(3):852-61. PubMed ID: 21493787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capromab pendetide. A review of its use as an imaging agent in prostate cancer.
    Lamb HM; Faulds D
    Drugs Aging; 1998 Apr; 12(4):293-304. PubMed ID: 9571393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
    Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease.
    Ponsky LE; Cherullo EE; Starkey R; Nelson D; Neumann D; Zippe CD
    Prostate Cancer Prostatic Dis; 2002; 5(2):132-5. PubMed ID: 12497003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunoguided surgery using indium-111 capromab pendetide (PROSTASCINT) to diagnose supraclavicular metastasis from prostate cancer.
    Anderson RS; Eifert B; Tartt S; King P
    Urology; 2000 Oct; 56(4):669. PubMed ID: 11018634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland.
    Mouraviev V; Madden JF; Broadwater G; Mayes JM; Burchette JL; Schneider F; Smith J; Tsivian M; Wong T; Polascik TJ
    J Urol; 2009 Sep; 182(3):938-47. PubMed ID: 19616259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer.
    Rieter WJ; Keane TE; Ahlman MA; Ellis CT; Spicer KM; Gordon LL
    Clin Nucl Med; 2011 Oct; 36(10):872-8. PubMed ID: 21892036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
    Koontz BF; Mouraviev V; Johnson JL; Mayes J; Chen SH; Wong TZ; Anscher MS; Sun L; Moul J; Polascik TJ
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):358-61. PubMed ID: 18164863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
    Schuster DM; Nieh PT; Jani AB; Amzat R; Bowman FD; Halkar RK; Master VA; Nye JA; Odewole OA; Osunkoya AO; Savir-Baruch B; Alaei-Taleghani P; Goodman MM
    J Urol; 2014 May; 191(5):1446-53. PubMed ID: 24144687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.
    Ellis RJ; Zhou EH; Fu P; Kaminsky DA; Sodee DB; Faulhaber PF; Bodner D; Resnick MI
    J Urol; 2008 May; 179(5):1768-73; discussion 1773-4. PubMed ID: 18343445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.